List view / Grid view
11 November 2013 | By Janssen Therapeutics EMEA
HCV is a major problem in the EMEA region, where an estimated 15 million people are living with the disease...
11 November 2013 | By Novartis
Spain-based Grifols to acquire Novartis blood transfusion diagnostics unit for USD 1.675 billion...
11 November 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces clinical experience with its angiotensin II receptor blocker (ARB) has reached 50 million patient-years of real world experience...
11 November 2013 | By AstraZeneca
Zoladex has been manufactured at AstraZeneca’s Macclesfield plant for over 25 years, supplying the medicine to more than one hundred markets around the world...
9 November 2013 | By Merck
“Patients in this study who took the investigational Timothy grass sublingual allergy immunotherapy tablet showed a significant improvement in common allergy symptoms..."
8 November 2013 | By Pfizer
The primary endpoint of the study was not achieved as there was not a statistically significant difference in renal function improvement...
7 November 2013 | By Amgen
Innovative program - Amgen Biotech Experience - brings real-world biotechnology lab experience to students...
7 November 2013 | By Abbott
Similac is trying to meet that resource need with the launch of StrongMoms Español, a free program that provides Hispanic moms relevant, Spanish-language resources...
6 November 2013 | By kdm communications limited
Quotient Clinical – the pioneer of Translational Pharmaceutics™ – will be showcasing the benefits of its unique, integrated approach to formulation development...
4 November 2013 | By GlaxoSmithKline
The results showed that the two-dose schedule in girls aged 9 to 14 years old induced immune responses...
4 November 2013 | By B3C Group GmbH
The collaboration aims to identify drug leads that block the activity of a number of challenging cancer therapeutic targets....
4 November 2013 | By Roche
Roche will make an upfront payment of CHF 35 million to Polyphor as well as payments upon reaching certain development...
4 November 2013 | By Johnson & Johnson
The resolution includes total settlement amounts of approximately $2 billion to the federal government...
2 November 2013 | By Creston Health
“The VALENCE results demonstrate the high efficacy of a 24-week, sofosbuvir-based, interferon-free treatment regimen for genotype 3 HCV patients..."
2 November 2013 | By Boehringer Ingelheim
"These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment..."
